Pneumococcal (PCV) vaccine side effects (Prevnar 20): VAERS data, trials and schedule
This page answers “pneumonia vaccine side effects” with sourced pharmacovigilance data — VAERS dose-adjusted rates and multi-system surveillance charts. Counts are database reports, not proven vaccine-caused injury rates.
How to read database counts: Pharmacovigilance systems (VAERS, EudraVigilance, Yellow Card, VigiBase, Lareb, DAEN) collect spontaneous, unverified reports. A report is not a confirmed adverse event and does not prove the vaccine caused the outcome. Under-reporting, stimulated reporting, and missing denominators limit rate interpretation. Compare with trials and epidemiological studies on each page before drawing conclusions.
Gold Standard EO (Aug 10, 2026)Federal recommendation status: Recommended for all children
The August 10, 2026 Executive Order on Gold Standard Childhood Vaccine Recommendations places pneumococcal disease in the Recommended for all children category. The EO also expresses a preference, to the maximum extent feasible, for administering all childhood immunizations at separate medical visits.
This page summarizes published pre-licensure and post-licensure data for pneumococcal conjugate vaccines (PCV) on the U.S. childhood schedule (Prevnar 13® — PCV13, and Prevnar 20® — PCV20). The older polysaccharide vaccine (PPSV23, Pneumovax® 23) is used in older children and adults with certain conditions but is not part of the routine childhood schedule. Safety and efficacy data are presented without interpretive language that implies the vaccine is "safe" or "unsafe."
Evidence state
For each outcome: the specific question, what controlled studies found, and how certain that evidence is on the GRADE scale (high, moderate, low, very low). Ratings are editorial judgments by the site applying GRADE to the studies in the table below — observational evidence starts at low and is rated up for large, consistent effects or a dose/age gradient, and down for inconsistency or imprecision (Methods). Where an effect is confined to a subgroup (for example young males), the question says so. "Not searched" means no controlled study has been compiled here yet; it is not a finding that the outcome is rare or caused by the vaccine.
Outcome & question
Finding & certainty
Why this rating
Febrile seizure
PCV13 (especially same day as influenza vaccine), children 6–59 months
increased risk (about 1 extra per 7,000 doses) Moderate certainty
Start low; +1 RR ≈ 2–2.5 in two independent VSD studies. Studies: Tse 2012, Duffy 2016.See table
Kawasaki disease
PCV13
no increased risk detected Low certainty
One self-controlled study, interval to 1.21. Studies: Kamidani 2022.See table
Guillain-Barré syndrome
PPSV23 (adults)
no increased risk detected Very low certainty
Single study, wide interval. Studies: Baxter 2013.See table
Anaphylaxis
Not searched
No controlled-study result is compiled for this outcome yet.
Myocarditis or pericarditis
Not searched
No controlled-study result is compiled for this outcome yet.
Immune thrombocytopenia
Not searched
No controlled-study result is compiled for this outcome yet.
1. Basic Information
Disease Protected Against
Streptococcus pneumoniae (Pneumococcus) is a bacterium causing invasive pneumococcal disease (IPD) including bacteremia and meningitis; pneumonia; and otitis media. Before vaccination, pneumococcus was the leading cause of bacterial meningitis and bacteremia in young children. There are >100 serotypes; PCV vaccines target the most clinically significant ones. IPD has a case-fatality rate of ~5–15% in children and can cause permanent neurological sequelae in meningitis survivors.
CDC Schedule (U.S., 2025)
Dose
Age
Product
Dose 1
2 months
PCV13 or PCV15 or PCV20
Dose 2
4 months
PCV13 or PCV15 or PCV20
Dose 3
6 months
PCV13 or PCV15 or PCV20
Dose 4 (booster)
12–15 months
PCV13 or PCV15 or PCV20
Source: CDC ACIP, 2025 schedule. PCV7 (7-valent) was introduced in 2000, replaced by PCV13 in 2010. PCV15 and PCV20 were licensed in 2021–2023. The schedule is transitioning to higher-valency products.
Licensed Pneumococcal (PCV) vaccine products
Each product has its own page with package-insert ingredients, side-effect data, lot lookup and comparisons with the other brands.
Structured composition for 1 branded product covered on this page,
taken from FDA-approved package inserts (DailyMed / manufacturer prescribing information).
Lists are per product — formulations differ by manufacturer and presentation.
Click an ingredient name to open its safety-context page when available.
ConjugateIntramuscular (IM)Adjuvant: Aluminum phosphateNo preservative (typical single-dose)Aluminum phosphatePolysorbate 80Yeast protein
Prevnar 20Pfizer Inc. · Conjugate
Delivery
Route: Intramuscular (IM)
Form: Suspension for injection
Dose volume: 0.5 mL
Presentation: single-dose prefilled syringe
Encapsulation / delivery vehicle
None (no nanoparticle/VLP encapsulation system)
Antigens
Antigen
Type
Amount / dose
Pneumococcal capsular polysaccharides (20 serotypes) conjugated to CRM197
Carrier: CRM197 (diphtheria CRM197 protein ≈51 mcg)
Conjugate
2.2 mcg each of 19 serotypes + 4.4 mcg serotype 6B (typical PCV20 labeling)
Ingredient lists are sourced from official package inserts for the specific brands named above.
Formulations can change between lots and over time — verify against the current label before any clinical decision.
Presence of a substance does not by itself indicate harm; toxicology is dose-, route-, and context-dependent.
Browse the full ingredient database:
Vaccine Ingredients index.
Causality assessment & potential mechanisms
Conditions below combine WHO-style causality levels with potential biological mechanisms
from the site mechanism catalog
(ae_mechanisms_catalog.json).
HRSA VICP table listing (where shown) indicates a compensable temporal association under U.S. program rules —
not automatic proof of causation for every case. Mechanisms are hypothesis-level pathways with graded evidence.
Pre-existing or newly formed IgE against vaccine antigens or excipients (e.g., gelatin, egg proteins, PEG, polysorbate) triggers mast-cell and basophil degranulation with systemic mediator release.
SIRVA
0–2 days
Very likely / Probable
Evidence: High
SIRVA — incorrect injection into shoulder structures (primary · procedural)
Needle placement into the subdeltoid/subacromial bursa or joint rather than deltoid muscle causes prolonged local inflammation and restricted range of motion (procedural, not antigen-specific).
Vaccine-induced fever lowers seizure threshold in susceptible young children; measles-containing vaccines show a well-documented risk window roughly 7–14 days post-dose.
Framework: WHO causality + HRSA VICP (where applicable) + AE mechanism catalog.
Last updated: 2026-07-18.
Schema: schemas/vaccine_injury_table.schema.json
· Mechanisms: schemas/ae_mechanism.schema.json.
Not medical or legal advice.
2. Pre-Licensure Clinical Trial Data
Licensure trial design (ICAN / OpenVAERS)
The table below reproduces ICAN’s No Placebo Table rows for U.S. childhood-schedule products relevant to this page — including the control/comparator used in FDA licensing trials (not always saline placebo). OSMF presents this for transparency; it is not an endorsement of ICAN interpretations.
Vaccine
Brand
Manufacturer
Doses (schedule)
Ages injected
Control / comparator
Placebo
Safety review window
PCV
Prevnar 13, PCV-13
Pfizer
4
2M 4M 6M 12M
Prevnar 7
No
6 months
PCV
Vaxneuvance PCV-15
Merck
4
2M 4M 6M 12M
Prevnar 13
No
6 months
PCV
Prevnar 20, PCV-20
Pfizer
4
2M 4M 6M 12M
Prevnar 13
No
6 months
PPSV23
Pneumovax 23
Merck
0 or 2
2Y+ if indicated
See note
No
See note
Source: OpenVAERS — No Placebo Table · ICAN original PDF
· Attribution: Informed Consent Action Network (ICAN) via OpenVAERS
· Last fetched: 2026-07-16.
For many trials listing '6 months' safety review, ICAN notes review was typically ~30 days post-injection with a phone call at 6 months.
PCV7 (Prevnar, 2000) was licensed based on a pivotal efficacy trial in ~38,000 infants — one of the largest pediatric vaccine pre-licensure programs. PCV13 (2010) was licensed based on immunogenicity non-inferiority trials comparing to PCV7 plus safety data from ~6,000 infants. PCV15 and PCV20 were licensed based on immunogenicity bridging studies.
Metric
PCV7 Data
PCV13 Data
Pivotal trial size
~38,000 infants (NCKP trial)
~6,000 infants (safety); immunogenicity in ~3,200
Efficacy (IPD, vaccine types)
~97%
Immunobridged; real-world data confirm high effectiveness
Similar to PCV7; slightly higher rate of local reactions compared to PCV7 due to additional serotypes
The PCV7 pivotal trial was notable for its size and for using a saline placebo, providing one of the most robust pre-licensure safety databases for any pediatric vaccine. PCV13 and subsequent products used active comparators (PCV7) rather than placebo.
Key Limitations
Serotype replacement: PCV vaccines reduce disease caused by vaccine serotypes, but non-vaccine serotypes can increase in prevalence (serotype replacement). This has been observed post-PCV7 and post-PCV13, necessitating development of higher-valency vaccines.
Febrile seizure risk with concomitant influenza vaccine: PCV13 given concomitantly with trivalent inactivated influenza vaccine (TIV) was associated with a small increased risk of febrile seizures in the 2010–2011 season (~1 additional seizure per 2,000–2,500 doses). This was not observed with PCV13 alone or with other concomitant vaccine combinations.
3. Post-Licensure Safety Data
PCV vaccines have extensive post-licensure safety data from VSD and VAERS, spanning >25 years for PCV7/PCV13. Key VSD findings:
Febrile seizures: PCV13 + TIV combination identified as a safety signal in VSD rapid cycle analysis (2010–2011). Signal resolved. PCV13 alone is not associated with increased febrile seizure risk.
No other consistent safety signals have been identified in VSD for PCV vaccines independently. IOM (2012) did not identify specific safety concerns for PCV.
⚠ Critical Caveat
VAERS data represent unverified reports. A report to VAERS does not mean the vaccine caused the event.
VAERS reports per million doses
U.S. VAERS reports for vaccinations given 2006–2024, divided by the 371 million doses distributed in the same years (HRSA, from CDC data).
All reports
266
per million doses (264–268) · 98,753 reports
Serious reports
28.1
per million doses · 10,449 reports (death, life-threatening, hospitalised or disabled)
Reports with a death
3.23
per million doses · 1,201 reports
These are reporting rates: they mix real reactions, coincidental events and reports of conditions that would have happened anyway, and they depend on how actively each vaccine is watched. Doses are distributed, not administered. Combination vaccines count toward each component in both numerator and denominator. Compare with the observed-vs-expected analysis and the controlled studies above. Data: vaers_reporting_rates.json.
All vaccines, per million doses
Vaccine
All
Serious
Death
pcv
266
28.1
3.23
rotavirus
157
27.9
4.08
hpv
335
25.3
2.00
hib
126
19.7
3.25
polio
152
17.6
2.77
mmr
320
15.3
0.94
varicella
372
14.1
0.84
hepatitis-b
110
12.7
2.15
meningococcal
214
11.8
0.70
dtap
132
11.2
1.31
hepatitis-a
152
8.5
0.58
influenza
68
5.4
0.48
What controlled safety studies found
Unlike VAERS counts, these studies compare vaccinated people with a control group or control time window, so they can estimate whether a risk is raised and by how much. 5 results for pneumococcal vaccines: 2 found an increased risk of a specific outcome, 3 found no increased risk.
Outcome
Design & population
Estimate (95% CI)
Excess per million doses
Finding
Source
Febrile seizures
PCV13 (adjusted for TIV)
self-controlled risk interval (VSD) Children 6-59 mo, US
Bars are drawn to scale within each comparison. Disease risks are per case of the disease; vaccine risks are the excess above background per dose, from controlled studies. How likely someone is to catch the disease, without vaccination, decides how these weigh up for an individual.
No single study measured both risks in the same population for this vaccine, so no side-by-side ratio is shown; the two lists below come from different studies, eras and populations.
Serious outcomes of the disease (per million cases)
Pneumococcal (invasive): Death from pneumococcal meningitis
Days from vaccination to onset in U.S. VAERS reports (0–180 days). A causal reaction usually starts inside a characteristic window; but people also report what happens soon after a shot, so each event is compared with all other reports for this vaccine. The Weibull shape measures bunching (below 1 = most onsets early).
Event
Reports
Median days
In risk window
Shape (95% CI) vs others
Reading
Seizure (any)
3,499
1
96% (others 98%)
0.74 (0.71–0.77) vs 0.76
same timing as other reports
Febrile seizure
1,078
1
97% (others 98%)
0.76 (0.73–0.81) vs 0.76
same timing as other reports
Intussusception
1,024
9
62% (others 47%)
0.85 (0.81–0.88) vs 0.76
spread later than other reports
Syncope
655
0
90% (others 80%)
0.82 (0.74–0.99) vs 0.76
same timing as other reports
Sudden infant death
305
3
71% (others 95%)
0.78 (0.71–0.84) vs 0.76
same timing as other reports
Guillain-Barré syndrome
245
9
83% (others 48%)
0.94 (0.84–1.04) vs 0.76
spread later than other reports
Herpes zoster
231
7
61% (others 48%)
0.52 (0.48–0.56) vs 0.76
clusters earlier than other reports
Anaphylaxis
175
0
93% (others 80%)
0.75 (0.61–1.23) vs 0.76
same timing as other reports
Bell's palsy / facial paralysis
86
1.5
74% (others 48%)
0.69 (0.60–0.93) vs 0.76
same timing as other reports
Stroke
84
1
65% (others 47%)
0.64 (0.55–0.79) vs 0.76
same timing as other reports
Kawasaki disease
81
5
78% (others 48%)
0.72 (0.65–0.84) vs 0.76
same timing as other reports
ADEM / encephalitis
72
4.5
65% (others 48%)
0.70 (0.62–0.83) vs 0.76
same timing as other reports
Timing alone cannot establish causation; it can make it more or less plausible. *Fitted on a random sample of 5,000 of these reports. Data: vaers_onset.json.
VAERS Reporting Data — Halma & Varon (2025), DARE-SAFE
The DARE-SAFE paper (Halma & Varon, Pharmacoepidemiology 2025, CC BY 4.0) analyzed VAERS reports for vaccines administered in the United States from 2006–2022. The following data are extracted from Table 1 of that paper for this vaccine (Pneumococcal (all pneumococcal conjugate + polysaccharide vaccines combined)):
Metric
Value
U.S. doses administered (2006–2022)
517,159,908
Total VAERS AE reports
83,537
AE reporting rate (per 100,000 doses)
16.2
Total death reports
810
Death reporting rate (per 100,000 doses)
0.157
AE-to-Death ratio
103:1
Source: Halma, M.; Varon, J. DARE-SAFE. Pharmacoepidemiology. 2025. DOI: 10.3390/pharma4020007. CC BY 4.0. Data from Table 1.
📚 Important Interpretive Caveats (from the paper itself)
Reporting rate ≠ incidence rate. VAERS is a passive, unverified system. A report means someone submitted a claim of temporal association, not a confirmed causal event. The paper is explicit that causality cannot be inferred from these numbers alone.
Reporting behavior is not uniform. More serious, unusual, or media-salient events are reported at much higher rates than mild ones. Products receiving more public, media, legal, and clinical attention (particularly COVID-19 vaccines, which also benefited from V-safe active-surveillance prompts and CICP compensation pathways) generate more reports per dose regardless of true risk.
Age and comorbidity confounding is not adjusted. COVID-19 vaccines were disproportionately administered to elderly and comorbid populations (nursing homes, 65+, high-risk groups in early 2021) with much higher background all-cause mortality than the general child/working-age population. Some fraction of temporally-associated deaths would occur regardless of vaccination, and the paper does not perform a background-rate comparison.
Stimulated reporting is a known, documented phenomenon. Media coverage, plaintiff attorney solicitation, and advocacy campaigns — all independently inflate VAERS reporting propensity. The paper cites this literature but does not correct for it.
Small-denominator rows are unreliable. Rates computed from small denominators (e.g., monovalent measles, DT, mumps, rubella) have enormous statistical uncertainty and should not be compared to vaccines with hundreds of millions of administered doses without noting the wide confidence intervals.
Source: Halma, M.; Varon, J. DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines. Pharmacoepidemiology. 2025, 4, 7. DOI: 10.3390/pharma4020007. CC BY 4.0.
Passive Surveillance: AE Type Breakdown (Multi-System)
Side-by-side view of U.S. VAERS, Health Canada Canada Vigilance, Japan JADER (PMDA), EU EudraVigilance, and live-scraped international systems via SurVigilance (VigiAccess, Lareb, DAEN, DMA, Medsafe). SurVigilance panels show MedDRA PT mention totals (not individual-case counts). Category assignment uses keyword matching — approximate, not official SOC coding. VAERS files on this site are built from the public VAERS download. FAERS figures use the public quarterly FAERS files. Counts are mentions or reports, not incidence.
VAERS (United States)
Canada Vigilance (Canada)
JADER (PMDA, Japan)
EudraVigilance (EU)
No matching vaccine cases in the current EudraVigilance DAP export.
This system’s totals are not in this panel. Published counts, when this site has them, are in the surveillance section.
DMA (Denmark)
Denmark DMA interactive ADR search is currently offline (Danish Medicines Agency IT transition; public overviews frozen at 12 Mar 2024). Live product PT tables cannot be retrieved until DKMA restores the search. See DKMA notice. Denmark continues to report into EU EudraVigilance (panel above).
Medsafe (New Zealand)
VAERS (U.S., 2006–2024): 178,458 symptom mentions (8.63/100k doses). Largest share: Injection-site / Local reaction (30%), Other / Unclassified (16%), General / Systemic (non-local) (15%). Canada Vigilance (CV Online extract): 3,089 reaction mentions in 797 unique reports (59.5% serious (474 of 797 reports)). Largest share: Injection-site / Local reaction (18%), Respiratory (13%), General / Systemic (non-local) (11%). JADER (PMDA public CSV extract): 4,585 reaction mentions in 2,068 unique reports (5.8% serious (120 of 2,068 reports)). Largest share: General / Systemic (non-local) (27%), Other / Unclassified (20%), Respiratory (19%). VigiAccess (WHO): 884,927 reaction-term mentions · search: pneumococcal. Largest share: Injection-site / Local reaction (23%), General / Systemic (non-local) (18%), Other / Unclassified (14%). Lareb (Netherlands): 10,567 reaction-term mentions · search: pneumococcal conjugate vaccine. Largest share: Injection-site / Local reaction (33%), General / Systemic (non-local) (17%), Other / Unclassified (16%). Medsafe (New Zealand): 1,334 reaction-term mentions · search: pneumococcal. Largest share: Injection-site / Local reaction (64%), General / Systemic (non-local) (16%), Gastrointestinal (6%). Cross-database note: All systems are passive and unverified; reporting rates are not directly comparable across countries (different populations, reporting incentives, and lack of dose denominators for Canada/Japan/EU). top VAERS: Injection-site / Local reaction; top Canada Vigilance: Injection-site / Local reaction; top JADER: General / Systemic (non-local). SurVigilance note: VigiAccess, Lareb, DAEN, DMA, and Medsafe counts are live-scraped MedDRA PT mention totals (not deduplicated individual cases). Data via SurVigilance (GPL-3.0; pip install SurVigilance). Category assignment uses keyword matching on reported reaction terms — approximate and exploratory. Neither database establishes causality.
Pharmacovigilance Lot Signal Detection — Hypothesis-Generating Only
Multi-system context below. VAERS (U.S.) supports lot-level volume z-scores and seriousness flags by product and lot (2006–2024). Each lot links to a summary with report count, seriousness %, adverse-event pie chart, U.S. state map, and timeline. A signal flag means a statistical threshold was exceeded — not that a lot is unsafe. Full dashboard →
VAERS flags:VOL high report volume (z ≥ 3) ·
BURST clustered in <90 days ·
SER serious reports >50%.
Lot numbers are voluntary/incomplete in VAERS. Location data is U.S. state only (no postal codes in the public extract).
VAERS (United States) — all lots by product
29,802 reports with usable lot across 1,462 lots · 244 flagged
Loading lot tables…
Other Pharmacovigilance Systems
Lot-level analysis is only possible where reporters supply batch/lot numbers in the public extract. Canada Vigilance, JADER (PMDA, Japan), and most other national systems publish product-level spontaneous reports without lot fields.
Canada Vigilance (Health Canada)
797 unique reports · 3,089 reaction mentions · 59.5% serious (474 of 797 reports). Top categories: Injection-site / Local reaction (18%), Respiratory (13%), General / Systemic (non-local) (11%).
Canada Vigilance spontaneous reports are unverified temporal associations. The public CV Online data extract does not include lot or batch numbers, so lot-level signal detection is not possible for this system — only product-level reaction patterns are shown here. No Canadian dose denominators are available. Extract 2026-03-31.
2,068 unique reports · 4,585 reaction mentions · 5.8% serious (120 of 2,068 reports). Top categories: General / Systemic (non-local) (27%), Other / Unclassified (20%), Respiratory (19%).
JADER (Japanese Adverse Drug Event Report database) spontaneous reports are unverified temporal associations; PMDA has not assessed causality per case. The public CSV extract does not include lot or batch numbers, so lot-level signal detection is not possible — only product-level reaction patterns are shown here. Reaction terms in source data use MedDRA/J Preferred Terms. JADER CSV extract pmdacasereport202606 (2026-06). JADER reference (PDF)
Active Pharmacovigilance (Defined-Population Surveillance)
Curated findings for Pneumococcal conjugate vaccines from active systems (not VAERS). Page inventory last reviewed: 2026-07-10.
ⓘ Active vs. passive — why this pane is separate
The VAERS / multi-system charts above are passive surveillance: spontaneous, unverified reports without a fixed denominator.
Active surveillance starts from a defined, enumerated population (EHR/claims or structured post-vaccination surveys), applies pre-specified statistical tests, and asks whether an outcome occurs
more often than expected in a risk window versus a comparison window or group.
These are not two flavors of the same evidence — active findings are the harder tier that can confirm, refute, or leave under investigation a signal first hinted in passive data.
Do not add VAERS report counts to active incidence rates.
○ No signal detected◐ Signal under investigation◑ Investigated — not confirmed● Signal confirmed (true association)– Not currently under active surveillance
CDC Vaccine Safety Datalink (VSD)
Outcome: Pre-specified serious outcomes after conjugate pneumococcal vaccination
Tier 2○ No signal detected
Pneumococcal conjugates have extensive active post-licensure monitoring. Higher-valency products continue RCA-style monitoring as they enter schedules; no confirmed signal has reversed the overall pediatric IPD-prevention indication.
Population
Infants and adults per product indications at VSD sites
Update cadence: Tier 1: check AusVaxSafety monthly when public pages update. Tier 2/3: quarterly review around ACIP meetings and PubMed/MMWR; set lastReviewed per record.
Source tiers: Tier 1 = public near-real-time dashboards (e.g. AusVaxSafety);
Tier 2 = VSD / Sentinel / PRAC-type findings released via ACIP slides, MMWR, or papers (no public VSD raw dashboard);
Tier 3 = regulator label/safety communications.
Detecting a signal and later classifying it as not confirmed is normal system behavior — not an anomaly to hide or amplify.
4. Documented Adverse Events
Rank-aggregated VAERS signal detection (rankv)
The table below lists vaccine–event pairs that were detected as disproportionality signals by all four base methods used in rankv (GPS, PRR, ROR, BCPNN) on multi-decade VAERS data, then ordered by rank aggregation (Borda average rank; related to the Spearman/GA top-list approach in the rankv paper).
Data: ~30 years of public VAERS (rankv processed tables).
Origin: precisionFDA “Gaining New Insights by Detecting Adverse Event Anomalies” challenge solution.
Caveat: Disproportionality signals are statistical associations in spontaneous reports. They do not establish causality, incidence, or product defect. Many top pairs reflect administration/product-use coding rather than clinical injury.
~35–40% reduction; substantial herd protection in unvaccinated and older adults
Otitis media
Very high; most common reason for pediatric antibiotic prescriptions
~20–25% reduction in all-cause otitis media visits; larger reduction in vaccine-type OM
Source: CDC Pink Book; MMWR. PCV has produced substantial herd protection, reducing IPD in unvaccinated adults and the elderly.
Disease Burden Over Time
Reported U.S. disease burden by year. The dashed vertical line marks vaccine introduction. Hover or tap data points for values; use arrow keys when a chart has focus.
ⓘ About these charts: These are accessible SVG line charts with keyboard navigation, hover tooltips, and an underlying data table (expand below). The dashed vertical line marks the year of vaccine introduction. Reported cases undercount true incidence; case definitions, reporting practices, and diagnostic methods have changed over time. See Section 5 for additional context and pre-vs-post era comparisons.
7. Evidence Summary
PCV vaccines have a robust evidence base. The PCV7 pivotal trial (N=38,000) was among the largest pediatric vaccine pre-licensure studies ever conducted, with a true saline placebo. Post-licensure VSD data span >25 years. The primary evidence gaps relate to serotype replacement dynamics (ongoing), the safety of newer higher-valency products relative to established products (post-licensure data still limited for PCV15/PCV20), and the long-term population-level impact of PCV on non-vaccine serotypes.
8. International Surveillance & Global Data
Quick links to public pharmacovigilance databases and trial registries relevant to Pneumococcal Conjugate Vaccine. Reporting counts do not establish causality.
Note: Spontaneous reports are unverified observations. Compare with epidemiological studies in Sections 3–6 before drawing conclusions.
9. Curated Adverse Event Literature
Curated peer-reviewed literature linking specific adverse events to Pneumococcal Vaccine. Each entry is a case report, case series, or related safety publication identified via PubMed. Expand Search PubMed for additional literature below to run custom queries.
Disclaimer: Published reports describe observations and associations; they do not establish population incidence or causality.
Common questions
How long do PCV (pneumococcal) vaccine side effects last?
Most reported PCV (pneumococcal) vaccine reactions are short-lived: injection-site soreness, tiredness, and low-grade fever that typically begin within a day or two and resolve within a few days. Longer-lasting or more serious events are rarer and are the ones tracked in the post-licensure surveillance and documented adverse-event sections of this page, with report counts that are not incidence rates. Anything severe or persisting beyond a week warrants medical review.
Is the PCV (pneumococcal) vaccine given to adults, and are side effects different in adults?
Whether the PCV (pneumococcal) vaccine is recommended for adults depends on the vaccine and the person's risk factors; the schedule and product sections above describe the licensed indications and age groups. Reporting patterns in adults can differ from children, so this page's VAERS and international database breakdowns should be read with the reporting population in mind. Check the current CDC/ACIP adult schedule and the product's prescribing information for adult dosing.
10. Key References
Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19(3):187–195. (NCKP trial)
IOM. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012.